Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients

Daumas, Aurélie; Magalon, Jérémy; Jouve, Élisabeth; Truillet, Romain; Casanova, Dominique; Guy, Laurent; Véran, Julie; Benyamine, A.; Dignat-George, Françoise; Magalon, G.; Sabatier, Florence; Granel, B.

doi:10.1016/j.retram.2016.10.006

Cited by 61 publications

(53 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this indication, collection of cell samples and their expansion, transport, preparation, cryopreservation, shipment to site of use and subsequent injection have all been important considerations and are primary logistical challenges of their clinical use. Use of the ADRCs has also improved outcomes in patients with systemic sclerosis (53–56) and improved healing of thermal burns (57). Cytori Therapeutics is developing ADRCs for thermal burn injury, including burns that are complicated by radiation exposure, and these ADRCs improved healing of full thickness burns in minipigs exposed to a sub-lethal dose of total body irradiation (TBI) – a radiation combined injury (58).…”

Section: Meeting Program Overview4mentioning

confidence: 99%

Cellular Therapies for Treatment of Radiation Injury: Report from a NIH/NIAID and IRSN Workshop

et al. 2017

View full text Add to dashboard Cite

In recent years, there has been increasing concern over the possibility of a radiological or nuclear incident occurring somewhere in the world. Intelligence agencies frequently report that terrorist groups and rogue nations are seeking to obtain radiological or nuclear weapons of mass destruction. In addition, there exists the real possibility that safety of nuclear power reactors could be compromised by natural (such as the tsunami and subsequent Fukushima accident in Japan in March, 2011) or accidental (Three Mile Island, 1979 and Chernobyl, 1986) events. Although progress has been made by governments around the world to prepare for these events, including the stockpiling of radiation countermeasures, there are still challenges concerning care of patients injured during a radiation incident. Because the deleterious and pathological effects of radiation are so broad, it is desirable to identify medical countermeasures that can have a beneficial impact on several tissues and organ systems. Cellular therapies have the potential to impact recovery and tissue/organ regeneration for both early and late complications of radiation exposure. These therapies, which could include stem or blood progenitor cells, mesenchymal stromal cells (MSCs) or cells derived from other tissues (e.g., endothelium or placenta), have shown great promise in treating other nonradiation injuries to and diseases of the bone marrow, skin, gastrointestinal tract, brain, lung and heart. To explore the potential use of these therapies in the treatment of victims after acute radiation exposure, the National Institute of Allergy and Infectious Diseases cosponsored an international workshop in July, 2015 in Paris, France with the Institut de Radioprotection et de Sûreté Nucléaire. The workshop included discussions of data available from testing in preclinical models of radiation injury to different organs, logistics associated with the practical use of cellular therapies for a mass casualty incident, as well as international regulatory requirements for authorizing such drug products to be legally and readily used in such incidents. This report reviews the data presented, as well as key discussion points from the meeting.

show abstract

Section: Meeting Program Overview4mentioning

confidence: 99%

Cellular Therapies for Treatment of Radiation Injury: Report from a NIH/NIAID and IRSN Workshop

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Fat tissue can be easily and safely harvested and SVF can be collected bedside making it an attractive therapeutic option for physicians to offer to their patients [19]. A variety of publications have reported on the injection of SVF including: osteoarthritis [20, -21], degenerative disc disease [22], sclerosis [23], tendinopathy [24], congestive heart failure [25], chronic obstructive pulmonary disease (COPD) [26], radiation necrosis [27], xerostomia [28], psoriasis [29], and multiple sclerosis [30].…”

Section: Introductionmentioning

confidence: 99%

Intra-Articular Implantation of Stromal Vascular Fraction Plus Platelet Rich Plasma in a Degenerative Meniscal Injury

Comella

Greenberg²,

Ross³

2018

J Med Cases

View full text Add to dashboard Cite

Regenerative medicine and specifically stem cell therapy is growing in popularity in a variety of orthopedic conditions including meniscal injuries. Stromal vascular fraction (SVF) which is easily obtained from adipose (fat tissue) is a mixture of adipose derived stem cells/ mesenchymal stem cells, pericytes, fibroblasts, progenitor/endothelial cells, and other cells. A mini-lipoaspiration procedure to obtain a small sample of fat can be completed using a cannula under local anesthesia. The SVF is separated from the adipocytes (fat cells) using enzyme digestion and centrifugation. Platelet rich plasma (PRP) from the peripheral blood is a mixture of growth factors and cytokines. We present a case study and to our knowledge first in man with a before and after arthroscopic evaluation showing the repair of a meniscal tear using SVF plus PRP. Adipose tissue (65 mL) was removed via a mini-lipoaspirate procedure under local anesthesia. Approximately 5 mL of whole fat was washed and prepared for injection. For the remaining 60 mL of fat, the adipocytes were removed after enzyme digestion and centrifugation to isolate the SVF. PRP (approximately 4 mL) was used to resuspend the cells for an intra-articular injection. The patient received five additional PRP injections of 2.5 mL at 3 -4 week intervals. The patient was monitored over a 12-month period for safety (including severe adverse events (SAEs) and adverse events) and quality of life parameters. In addition, an arthroscopic evaluation was completed at baseline and 9 months post procedure. There were no reported SAEs or other safety complications during the procedure or the follow-up time period. The patient demonstrated reduction of pain with clearly visible repair on the arthroscopic evaluation. The patient expressed an overall improvement in quality of life and willingness to repeat PRP treatments. Based on the outcomes of this case study, intra-articular injection of SVF plus PRP could be a feasible treatment plan for a patient with chronic meniscus injury.

show abstract

“…Comella et al reported on the safety of SVF in a variety of indications with various delivery methods. Other publications have demonstrated success of SVF for specific conditions including: chronic obstructive pulmonary disease (COPD) [17], congestive heart failure [18], degenerative disc disease [19], osteoarthritis/orthopedics [20][21][22][23][24], radiation necrosis [25], sclerosis [26], tendinopathy [27], xerostomia [28], psoriasis [29] and multiple sclerosis [30]. The following is a case report and to our knowledge first in man a single injection of SVF and PRP into a chronic non-healing stage 3 ulcer in a patient with an incomplete spinal cord injury.…”

Section: Introductionmentioning

confidence: 99%

Injection of Stromal Vascular Fraction Plus Platelet-Rich Plasma in a Non-Healing Decubitus Ulcer

Comella

Ikudayisi

2018

J Med Cases

View full text Add to dashboard Cite

Non-healing decubitus ulcers can be challenging to treat and may often progress to other life-threatening complications. Significant tissue damage is present in stage 3/4 wounds and treatment options can be limited or present additional risks. Applications of regenerative medicine and stem cell therapy are rapidly expanding in particular in the field of non-healing wounds. Adipose tissue is a rich source of autologous stem cells which can be easily isolated in an outpatient visit. The population of cells collected from fat after the adipocytes (fat cells) are removed via centrifugation is called stromal vascular fraction (SVF) and contains mesenchymal/adipose stem cells, fibroblasts, pericytes, endothelial/progenitor cells and more. Adipose tissue is collected under local anesthesia via cannula and SVF is separated via centrifugation after enzyme digestion. In addition, peripheral blood can be centrifuged to collect platelet-rich plasma (PRP) which contains a mixture of cytokines/growth factors. Here we present a first in man case study of a single injection of SVF and PRP into a chronic non-healing stage 3 ulcer in a patient with an incomplete spinal cord injury. After removing approximately 60 mL of fat tissue, the SVF was isolated and resuspended in approximately 5 mL of PRP for local administration in the non-healing wound. The wound was monitored and tracked with imaging and the patient was tracked for quality of life parameters as well as safety (adverse events). No complications or other safety events were reported either during the procedure or in the months following the procedure. The patient reported reduction of pain consistent with wound healing and a willingness to repeat therapies if required. The healing stage 3 pressure injury showed clear re-epithelialization. Based on this case study, a feasible treatment plan to promote healing for stage 3 and 4 decubitus ulcers could be a single injection of SVF plus PRP.

show abstract

Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients

Cited by 61 publications

References 6 publications

Cellular Therapies for Treatment of Radiation Injury: Report from a NIH/NIAID and IRSN Workshop

Cellular Therapies for Treatment of Radiation Injury: Report from a NIH/NIAID and IRSN Workshop

Intra-Articular Implantation of Stromal Vascular Fraction Plus Platelet Rich Plasma in a Degenerative Meniscal Injury

Injection of Stromal Vascular Fraction Plus Platelet-Rich Plasma in a Non-Healing Decubitus Ulcer

Contact Info

Product

Resources

About